To view this email as a web page, click here.
 
FDA warns maker of ingredient in huge heart drug recall
After an expanded recall of the blood pressure medication valsartan and other drugs, FDA is warning the manufacturer of the carcinogenic ingredient involved.
Read more
 
In-clinic autoimmune treatment gets boost from novel cell therapy
From our sister brand, Managed Healthcare Executive: A new Chinese study highlights a potential cell therapy strategy for autoimmune diseases in a clinic setting.
Read more
 
FDA clears Tecentriq-Avastin combo for first-line treatment of lung cancer
A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.